Here are the 10-K annual reports from Azitra Inc (AZTR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow AZTR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AZTR filings page.
Azitra, Inc. files its annual report describing an early-stage biopharmaceutical business focused on precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary microbial library of about 1,500 bacterial strains supported by artificial intelligence and licensed genetic engineering technology.
Its lead programs are ATR-12 for Netherton syndrome, ATR-04 for epidermal growth factor receptor inhibitor–associated rash, and ATR-01 for ichthyosis vulgaris, all using modified Staphylococcus epidermidis. Azitra highlights academic and technology partnerships, an IP portfolio including U.S. and foreign patents, and extensive regulatory, financing, clinical, competitive, and operational risks typical for an early-stage biotech without commercial products.